13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001631134
Total reported value
$1.9B
$1.9B
58 檔
30.7%
At the close of Q2 2025, Sofinnova Investments, Inc. disclosed equity holdings valued at approximately $1.9B, spread across 58 reported holdings.
Sofinnova Investments, Inc. executed strategic sector rebalancing during Q2 2025, establishing 13 new positions while fully exiting 17 holdings and trimming 17 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 16.02% | +9.98% | — | |
| 2 | GILD | Gilead Sciences Inc | Stock-Healthcare | 7.12% | +2.24% | NEW | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.63% | — | +83.75% | |
| 4 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.50% | +0.25% | +36.08% | |
| 5 | VERA | Vera Therapeutics Inc | Stock-Other | 4.03% | +1.93% | — | |
| 6 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 3.30% | -5.66% | EXIT | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.13% | +0.85% | +81.50% | |
| 8 | ABBV | Abbvie Inc | Stock-Healthcare | 3.02% | — | — | |
| 9 | IBB | Ishares Biotechnology ETF | ETF-Tech | 2.90% | -3.05% | EXIT | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.83% | — | — | |
| 11 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.82% | -0.50% | EXIT | |
| 12 | DXCM | Dexcom Inc | Stock-Healthcare | 2.80% | -0.94% | EXIT | |
| 13 | IDYA | Ideaya Biosciences Inc | Stock-Other | 2.76% | +0.35% | -18.09% | |
| 14 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.62% | -1.15% | EXIT | |
| 15 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.35% | +0.82% | NEW | |
| 16 | AVBP | Arrivent Biopharma Inc | Stock-Other | 2.26% | +1.56% | — | |
| 17 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.13% | -0.02% | EXIT | |
| 18 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.08% | -3.28% | — | |
| 19 | INSM | Insmed Inc | Stock-Healthcare | 1.93% | -1.28% | +3.18% | |
| 20 | REPL | Replimune Group Inc | Stock-Other | 1.88% | -0.30% | EXIT | |
| 21 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.79% | — | +7.60% | |
| 22 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 1.54% | +0.62% | +53.50% | |
| 23 | ANAB | Anaptysbio Inc | Stock-Other | 1.40% | +1.20% | -11.01% | |
| 24 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.39% | +1.84% | — | |
| 25 | QURE | uniQure N.V. | Stock-Other | 1.33% | — | +185.53% | |
| 26 | COGT | Cogent Biosciences Inc | Stock-Other | 1.32% | -1.02% | +38.19% | |
| 27 | ✓ | Merus N V | Stock-Other | 1.30% | — | — | |
| 28 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.26% | — | — | |
| 29 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.12% | — | -35.11% | |
| 30 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.05% | — | — | |
| 31 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.05% | — | — | |
| 32 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.02% | — | +53.92% | |
| 33 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.91% | — | — | |
| 34 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.87% | — | -33.00% | |
| 35 | ✓ | Immatics NV | Stock-Other | 0.74% | +0.56% | +44.15% | |
| 36 | EXK | Exact Sciences CORP | Stock-Materials | 0.68% | — | — | |
| 37 | PHVS | Pharvaris N.V. | Stock-Other | 0.63% | +0.70% | -1.33% | |
| 38 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.62% | +0.44% | +1.54% | |
| 39 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.61% | +0.75% | +17.18% | |
| 40 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 0.61% | — | — | |
| 41 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.60% | -0.62% | -46.61% | |
| 42 | BIOA | Bioage Labs Inc | Stock-Other | 0.58% | +1.39% | — | |
| 43 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.57% | +0.34% | +8.19% | |
| 44 | IMNM | Immunome Inc | Stock-Other | 0.44% | +0.47% | -1.29% | |
| 45 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.36% | +0.77% | -14.23% | |
| 46 | SVRA | Savara Inc | Stock-Other | 0.34% | +0.04% | -55.17% | |
| 47 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.20% | — | — | |
| 48 | NXTCEUR | Nextcure Inc | Stock-Other | 0.08% | — | — | |
| 49 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.07% | -0.07% | EXIT | |
| 50 | JBIO | Jade Biosciences Inc | Stock-Other | 0.07% | +0.06% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | +4.1% | +150.73% | Add |
| 2 | ABBV | Abbvie Inc | +3% | NEW | New buy |
| 3 | IBB | Ishares Biotechnology ETF | +2.9% | NEW | New buy |
| 4 | BSX | Boston Scientific CORP | +2.8% | NEW | New buy |
| 5 | UTHR | United Therapeutics CORP | +2.1% | NEW | New buy |
| 6 | ROIV | Roivant Sciences Ltd. | +2% | +219.56% | Add |
| 7 | ISRG | Intuitive Surgical Inc | +2% | +489.47% | Add |
| 8 | LLY | Eli Lilly & Co | +1.8% | +83.75% | Add |
| 9 | NTRA | Natera Inc | +1.7% | — | Unchanged |
| 10 | RYTM | Rhythm Pharmaceuticals Inc | +1.6% | +81.50% | Add |
| 11 | ✓ | Merus N V | +1.3% | NEW | New buy |
| 12 | AZNN | Astrazeneca Plc-spons Adr | +1.3% | NEW | New buy |
| 13 | CDTX | Cidara Therapeutics Inc | +1.1% | NEW | New buy |
| 14 | DXCM | Dexcom Inc | +1% | +32.25% | Add |
| 15 | BBIO | Bridgebio Pharma Inc | +1% | +35.26% | Add |
| 16 | QURE | uniQure N.V. | +1% | +185.53% | Add |
| 17 | SMMT | Summit Therapeutics Inc | +0.9% | NEW | New buy |
| 18 | ✓ | Inozyme Pharma Inc | +0.8% | — | Unchanged |
| 19 | EXK | Exact Sciences CORP | +0.7% | NEW | New buy |
| 20 | COGT | Cogent Biosciences Inc | +0.5% | +38.19% | Add |
| 21 | AKRO | Akero Therapeutics Inc | +0.4% | +7.60% | Add |
| 22 | SUPN | Supernus Pharmaceuticals Inc | +0.4% | +53.50% | Add |
| 23 | INSM | Insmed Inc | +0.4% | +3.18% | Add |
| 24 | JAZZ | Jazz Pharmaceuticals plc | +0.4% | +36.08% | Add |
| 25 | REPL | Replimune Group Inc | +0.3% | +33.33% | Add |
| 26 | RNAGBP | Avidity Biosciences Inc | +0.3% | +53.92% | Add |
| 27 | ✓ | Immatics NV | +0.3% | +44.15% | Add |
| 28 | AVBP | Arrivent Biopharma Inc | +0.2% | — | Unchanged |
| 29 | APGE | Apogee Therapeutics Inc | +0.2% | NEW | New buy |
| 30 | IMNM | Immunome Inc | +0.1% | -1.29% | Trim |
| 31 | RAPP | Rapport Therapeutics Inc | +0.1% | — | Unchanged |
| 32 | RCUS | Arcus Biosciences Inc | +0.1% | +17.18% | Add |
| 33 | JBIO | Jade Biosciences Inc | +0.1% | NEW | New buy |
| 34 | BOLT | Bolt Biotherapeutics Inc | +0.1% | NEW | New buy |
| 35 | WVE | Wave Life Sciences Ltd. | +0.1% | NEW | New buy |
| 36 | PHVS | Pharvaris N.V. | 0% | -1.33% | Trim |
| 37 | BIOA | Bioage Labs Inc | 0% | — | Unchanged |
| 38 | GPCR | Structure Therapeutics Inc | — | -1.71% | Trim |
| 39 | NXTCEUR | Nextcure Inc | — | — | Unchanged |
| 40 | ✓ | Ikena Oncology Inc | — | — | Unchanged |
| 41 | IRON | Disc Medicine Inc | — | -2.31% | Trim |
| 42 | ANAB | Anaptysbio Inc | 0% | -11.01% | Trim |
| 43 | ✓ | Establishment Labs Holdings In | 0% | -1.94% | Trim |
| 44 | ✓ | 0% | -1.65% | Trim | |
| 45 | INBX | Inhibrx Biosciences Inc | 0% | +1.54% | Add |
| 46 | YMABUSD | Y-mabs Therapeutics Inc | 0% | — | Unchanged |
| 47 | ELVN | Enliven Therapeutics Inc | 0% | EXIT | Sold out |
| 48 | VIR | Vir Biotechnology Inc | 0% | EXIT | Sold out |
| 49 | IDYA | Ideaya Biosciences Inc | -0.1% | -18.09% | Trim |
| 50 | BOLT1EUR | Bolt Biotherapeutics Inc | -0.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Sofinnova Investments, Inc. reported a total U.S. public equity portfolio value of $1.9B across 58 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, GILD, LLY) accounted for 30.7% of total reported equity market value during Q2 2025.
Top New Position Initiated
ABBV
市值: $49.3M
Top Position Liquidated / Trimmed
SYK
前期市值: $111.1M
During Q2 2025, Sofinnova Investments, Inc.'s top holdings by market value included NTRA (16.0%)、GILD (7.1%)、LLY (4.6%). The largest single position, NTRA, represented 16.0% of total portfolio value.
In Q2 2025, Sofinnova Investments, Inc. made 66 total portfolio adjustments, initiating 13 new buys, adding to 19 positions, trimming 17 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.